Is FHTX or CLNN more profitable?

Foghorn Therapeutics has a net margin of -266.88% compared to Clene's net margin of -25,009.70%. Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics -266.88% N/A -35.38% Clene -25,009.70% N/A -137.98%

Does the media prefer FHTX or CLNN?

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Clene. MarketBeat recorded 4 mentions for Foghorn Therapeutics and 3 mentions for Clene. Clene's average media sentiment score of 1.89 beat Foghorn Therapeutics' score of 0.82 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CLNN or RNAC more profitable?

Cartesian Therapeutics has a net margin of -8,550.65% compared to Clene's net margin of -25,009.70%. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Cartesian Therapeutics -8,550.65% N/A -28.25%

Does the media refer more to CLNN or RNAC?

In the previous week, Clene and Clene both had 3 articles in the media. Clene's average media sentiment score of 1.89 beat Cartesian Therapeutics' score of 0.63 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TKNO or CLNN?

Alpha Teknova has higher revenue and earnings than Clene. Alpha Teknova is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Teknova $40.52M 7.19 -$17.26M -$0.32 N/A Clene $200K 407.36 -$26.17M -$3.20 N/A

Is TKNO or CLNN more profitable?

Alpha Teknova has a net margin of -41.07% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Alpha Teknova's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Teknova -41.07% -24.32% -16.34% Clene -25,009.70% N/A -137.98%

Does the media refer more to CLNN or NMRA?

In the previous week, Neumora Therapeutics had 2 more articles in the media than Clene. MarketBeat recorded 5 mentions for Neumora Therapeutics and 3 mentions for Clene. Clene's average media sentiment score of 1.89 beat Neumora Therapeutics' score of 0.52 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Clene (CLNN) Competitors

$6.38 -0.02 (-0.23%)

As of 10:16 AM Eastern

Compare

CLNN vs. FHTX, RNAC, TKNO, NMRA, and ELDN

Should you buy Clene stock or one of its competitors? MarketBeat compares Clene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clene include Foghorn Therapeutics (FHTX), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), Neumora Therapeutics (NMRA), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.

How does Clene compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Clene has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	10.42	-$74.28M	-$1.16	N/A
Clene	$200K	407.36	-$26.17M	-$3.20	N/A

Foghorn Therapeutics presently has a consensus price target of $11.43, suggesting a potential upside of 108.36%. Clene has a consensus price target of $33.25, suggesting a potential upside of 421.57%. Given Clene's higher probable upside, analysts plainly believe Clene is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Foghorn Therapeutics has a net margin of -266.88% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Clene	-25,009.70%	N/A	-137.98%

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Clene. MarketBeat recorded 4 mentions for Foghorn Therapeutics and 3 mentions for Clene. Clene's average media sentiment score of 1.89 beat Foghorn Therapeutics' score of 0.82 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Foghorn Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Clene has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Summary

Foghorn Therapeutics beats Clene on 9 of the 15 factors compared between the two stocks.

How does Clene compare to Cartesian Therapeutics?

Clene (NASDAQ:CLNN) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

23.3% of Clene shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cartesian Therapeutics has a net margin of -8,550.65% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

In the previous week, Clene and Clene both had 3 articles in the media. Clene's average media sentiment score of 1.89 beat Cartesian Therapeutics' score of 0.63 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has higher earnings, but lower revenue than Cartesian Therapeutics. Clene is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	407.36	-$26.17M	-$3.20	N/A
Cartesian Therapeutics	$2.80M	92.81	-$130.30M	-$5.90	N/A

Clene presently has a consensus price target of $33.25, suggesting a potential upside of 421.57%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 268.57%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Clene is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Clene has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Summary

Clene beats Cartesian Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Clene compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Alpha Teknova has higher revenue and earnings than Clene. Alpha Teknova is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	7.19	-$17.26M	-$0.32	N/A
Clene	$200K	407.36	-$26.17M	-$3.20	N/A

Alpha Teknova has a net margin of -41.07% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Clene	-25,009.70%	N/A	-137.98%

In the previous week, Clene had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for Clene and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 equaled Clene'saverage media sentiment score.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Clene	Very Positive

Alpha Teknova presently has a consensus target price of $8.00, indicating a potential upside of 47.28%. Clene has a consensus target price of $33.25, indicating a potential upside of 421.57%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Alpha Teknova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Clene has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Clene beats Alpha Teknova on 10 of the 16 factors compared between the two stocks.

How does Clene compare to Neumora Therapeutics?

Clene (NASDAQ:CLNN) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

In the previous week, Neumora Therapeutics had 2 more articles in the media than Clene. MarketBeat recorded 5 mentions for Neumora Therapeutics and 3 mentions for Clene. Clene's average media sentiment score of 1.89 beat Neumora Therapeutics' score of 0.52 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Neumora Therapeutics has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Clene has higher revenue and earnings than Neumora Therapeutics. Clene is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	407.36	-$26.17M	-$3.20	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

23.3% of Clene shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Clene presently has a consensus price target of $33.25, indicating a potential upside of 421.57%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 312.00%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Clene has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

Summary

Neumora Therapeutics beats Clene on 8 of the 15 factors compared between the two stocks.

How does Clene compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eledon Pharmaceuticals presently has a consensus target price of $9.67, indicating a potential upside of 152.00%. Clene has a consensus target price of $33.25, indicating a potential upside of 421.57%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Clene had 2 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for Clene and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 equaled Clene'saverage media sentiment score.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Clene	Very Positive

Eledon Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Clene	-25,009.70%	N/A	-137.98%

Clene has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Clene	$200K	407.36	-$26.17M	-$3.20	N/A

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Clene has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Summary

Clene beats Eledon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Clene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLNN vs. The Competition

Export

Metric	Clene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$81.47M	$3.64B	$6.76B	$12.50B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.99	20.96	26.93	24.41
Price / Sales	407.36	313.81	586.18	117.36
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	-3.94	8.50	10.94	6.33
Net Income	-$26.17M	$23.83M	$3.58B	$330.66M
7 Day Performance	4.17%	-3.12%	-2.10%	-0.66%
1 Month Performance	9.16%	6.61%	3.21%	-0.14%
1 Year Performance	70.91%	48.58%	26.34%	20.16%

Clene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLNN Clene	3.8455 of 5 stars	$6.38 -0.2%	$33.25 +421.6%	+78.0%	$81.47M	$200K	N/A	100	News Coverage Positive News Gap Down
FHTX Foghorn Therapeutics	2.8325 of 5 stars	$5.05 -4.7%	$11.43 +126.3%	+0.7%	$311.18M	$30.91M	N/A	120	News Coverage Analyst Downgrade
RNAC Cartesian Therapeutics	3.091 of 5 stars	$10.34 -2.4%	$32.60 +215.3%	-35.2%	$311.15M	$2.80M	N/A	64	Gap Up
TKNO Alpha Teknova	2.4031 of 5 stars	$5.53 -4.5%	$8.00 +44.7%	+12.5%	$310.42M	$40.52M	N/A	240	Positive News
NMRA Neumora Therapeutics	3.7824 of 5 stars	$1.69 +1.2%	$6.86 +305.7%	+24.0%	$309.42M	N/A	N/A	108	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLNN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clene (CLNN) Competitors

CLNN vs. FHTX, RNAC, TKNO, NMRA, and ELDN

How does Clene compare to Foghorn Therapeutics?

Summary

How does Clene compare to Cartesian Therapeutics?

Summary

How does Clene compare to Alpha Teknova?

Summary

How does Clene compare to Neumora Therapeutics?

Summary

How does Clene compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clene (CLNN) Competitors

CLNN vs. FHTX, RNAC, TKNO, NMRA, and ELDN

How does Clene compare to Foghorn Therapeutics?

Which has higher earnings & valuation, FHTX or CLNN?

Do analysts rate FHTX or CLNN?

Is FHTX or CLNN more profitable?

Do insiders and institutionals have more ownership in FHTX or CLNN?

Does the media prefer FHTX or CLNN?

Which has more volatility and risk, FHTX or CLNN?

Summary

How does Clene compare to Cartesian Therapeutics?

Do insiders & institutionals hold more shares of CLNN or RNAC?

Is CLNN or RNAC more profitable?

Does the media refer more to CLNN or RNAC?

Which has higher valuation and earnings, CLNN or RNAC?

Do analysts rate CLNN or RNAC?

Which has more volatility & risk, CLNN or RNAC?

Summary

How does Clene compare to Alpha Teknova?

Which has preferable valuation and earnings, TKNO or CLNN?

Is TKNO or CLNN more profitable?

Does the media favor TKNO or CLNN?

Do analysts rate TKNO or CLNN?

Which has more volatility & risk, TKNO or CLNN?

Do institutionals and insiders believe in TKNO or CLNN?

Summary

How does Clene compare to Neumora Therapeutics?

Does the media refer more to CLNN or NMRA?

Is CLNN or NMRA more profitable?

Which has better earnings and valuation, CLNN or NMRA?

Do insiders and institutionals believe in CLNN or NMRA?

Do analysts prefer CLNN or NMRA?

Which has more risk & volatility, CLNN or NMRA?

Summary

How does Clene compare to Eledon Pharmaceuticals?

Do insiders and institutionals believe in ELDN or CLNN?

Do analysts rate ELDN or CLNN?

Does the media prefer ELDN or CLNN?

Is ELDN or CLNN more profitable?

Which has preferable earnings & valuation, ELDN or CLNN?

Which has more volatility and risk, ELDN or CLNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools